Open AccessBudget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
Author(s) -
Yiling Jiang,
Eric Sarpong,
P.S. Sears,
N Engels
Publication year - 2021
Publication title -
infectious diseases and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.399
H-Index - 28
eISSN - 2193-8229
pISSN - 2193-6382
DOI - 10.1007/s40121-021-00480-0
Subject(s) - fidaxomicin , medicine , clostridioides , vancomycin , population , pediatrics , emergency medicine , environmental health , biology , bacteria , genetics , staphylococcus aureus
Fidaxomicin is as effective as vancomycin in treating Clostridioides difficile infection (CDI) but more effective at preventing recurrence. However, because fidaxomicin is more costly than vancomycin, its overall value in managing CDI is not well understood. This study assessed the budget impact of introducing fidaxomicin versus vancomycin for the treatment of adults with CDI from a hospital perspective in the US.